Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IBO with free AI briefings, catalyst countdowns, and dilution alerts.

IBO · IMPACT BIOMEDICAL INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$21,000 Cash on Hand
CF+ Cash Runway
11.2% Short Interest
Follow IBO by email Get an email when IBO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IBO, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Tenofovir HIV Early Phase 1 · NCT04898699 Completed
Artemether-Lumefantrine Drug Combination Malaria Phase 4 · NCT05340153 Unknown
Dihydroartemisinin-Piperaquine drug combination Malaria Phase 4 · NCT05340153 Unknown
Fedratinib Primary Myelofibrosis Phase 3 · NCT03952039 Completed
IMP4927 Ovarian Cancer Phase 3 · NCT04169997 Active not recruiting
Senaparib (IMP4297) Ovary Cancer Phase 2 · NCT06617923 Active not recruiting
ATR Inhibitor IMP9064 Solid Tumor Phase 1/2 · NCT05269316 Recruiting
PARP1 Inhibitor IMP1734 Advanced Solid Tumor Phase 1/2 · NCT06253130 Recruiting
PARP1 Inhibitor EIK1004 Advanced Solid Tumors Phase 1/2 · NCT06907043 Recruiting
Potrasertib (IMP7068) Advanced Solid Tumors Phase 1 · NCT04768868 Unknown
14C-IMP4297 Solid Tumor Phase 1 · NCT05109832 Completed

Also used in these trials (approved or third-party drugs, not IBO's own candidates): Emtricitabine And Tenofovir Disoproxil Fumarate, Anti-Thymocyte Globulin (Rabbit), Temozolomide, Sirolimus, Mycophenolate Mofetil, Cyclosporine, Cyclophosphamide, Fluconazole.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IBO holds $21,000 in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IBO files for a raise →

👥 Who Owns IBO

Insiders 11.1% Institutions 16.3% Public and other holders 72.6%
HolderTypeShares% of sharesAs of
Vanguard Group Inc Institution (13F) 814,885 9.43% 2025-12-31
DSS, INC.
10% owner
Insider 589,518 6.82% 2026-09-22
Blackrock Inc. Institution (13F) 259,946 3.01% 2025-12-31
Millennium Management Llc Institution (13F) 137,823 1.60% 2025-12-31
Frank D Heuszel
Chief Executive Officer, Director
Insider 97,344 1.13% 2024-12-05
Geode Capital Management, LLC Institution (13F) 74,378 0.86% 2025-12-31
Two Sigma Investments, LP Institution (13F) 39,827 0.46% 2025-12-31
David K Keene
Director
Insider 32,112 0.37% 2026-10-07
Mark Suseck
Chief Operating Officer
Insider 32,112 0.37% 2026-10-07
Christian Thomas Zimmerman
Director
Insider 32,112 0.37% 2026-10-07
Elise Brownell
Director
Insider 32,112 0.37% 2026-10-07
Castel Berisford Hibbert
Director
Insider 32,112 0.37% 2026-10-07

Share count 8,640,000 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2025-12-31). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-09-24
filed 2026-09-24
DSS, INC.
Sale (S) 156 $7.06 589,518
2026-09-23
filed 2026-09-24
DSS, INC.
Sale (S) 27 $6.95 589,674
2026-09-22
filed 2026-09-24
DSS, INC.
Sale (S) 723 $0.55 589,701
2026-03-27
filed 2026-03-30
Macko Todd D
Sale (S) 43,400 $0.56 155,122
2026-03-25
filed 2026-03-30
Macko Todd D
Sale (S) 1,600 $0.60 198,122

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full IBO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IBO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.